Pharmaceutical Economics

By Chressanthis, George | Business Economics, July 2008 | Go to article overview

Pharmaceutical Economics

Chressanthis, George, Business Economics

Much has been written in various issues of Business Economics over the years about the healthcare industry. Yet, and rather surprisingly, a lack of insight exists into the role economists play in shaping the direction and outcome of business research and policy decisions of a very important part of the healthcare industry--the pharmaceutical industry.

The main skills sought after by drug companies are in the science and manufacturing operations areas. Drug discovery and research and development (R&D) will always represent the life-blood of a pharmaceutical company. The role of scientists to ensure a steady pipeline of novel therapies that address unmet patient needs and manufacturing operations to produce those drugs will always be critical. However, with growing economic challenges facing the industry, more efforts are being placed on novel ways that these new drugs can be commercialized in the marketplace. Thus, the technical skills of an economist are needed more than ever to address the growing challenges faced by individual companies and the industry. Whether operating within a pharmaceutical company or as a consultant to the industry, these skills must be combined with expert communication and leadership capabilities. But to convince the reader, I need to address the questions you may have.

Why Work in the Pharmaceutical Industry?

The drug industry is ultimately about serving the needs of patients. Spending on pharmaceuticals represents around 11 percent of total healthcare spending, which in turn is over 14 percent of gross domestic product (GDP) and rising. Long-term demographic trends favor the industry with an increasing portion of the population reaching retirement age, implying disproportionate spending on healthcare and drugs. Moreover, due to the passage of Medicare Part D, which now provides a drug benefit to seniors within Medicare, the larger group of baby-boomers reaching retirement age will increase the demand for novel and effective therapies that prolong a productive life.

Numerous academic studies show the value of pharmaceuticals on the quality and quantity of life and, in turn, social efficiency. Also, early identification and intervention of appropriate pharmaceutical care across a wide range of therapy areas such as cardiovascular, central nervous system, oncology, respiratory, and gastrointestinal diseases can greatly reduce medical costs to treat patients. Non-intervention or delays in treating such conditions both worsen disease severity and require more invasive procedures and costly hospitalization. In short, the drugs produced by the pharmaceutical industry generate significant positive externality benefits to society. Thus, for those people looking to make a difference in the lives of people, there are few industries that can compare to the pharmaceutical industry.

The challenges that the pharmaceutical industry faces would interest an economist having both the skills and insights to investigate and solve the following issues:

* Economic analysis needed to inform decision makers on the portfolio asset allocation of R&D investments is becoming more and more critical. Drug discovery and R&D costs are increasing, as investments in drug pipelines require ever greater resources to generate differentiable and novel approaches to treat diseases. Current estimates are that, on average, it takes about 13 years and $932 million of development costs to bring a new chemical entity to market. This cost estimate does not include sales and marketing costs to commercialize the product once launched.

* An economist will be challenged to find a solution to the relentless pressure to reduce drug costs and improve the efficacy of new drug therapies for people in every country. Accessibility to drug medications is a key public policy issue across the globe. For example, regulation of drug pricing (especially in Europe), drug importation, and public reimbursement plans weigh heavily in favor of generics over branded pharmaceuticals. …

The rest of this article is only available to active members of Questia

Already a member? Log in now.

Notes for this article

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
One moment ...
Default project is now your active project.
Project items

Items saved from this article

This article has been saved
Highlights (0)
Some of your highlights are legacy items.

Highlights saved before July 30, 2012 will not be displayed on their respective source pages.

You can easily re-create the highlights by opening the book page or article, selecting the text, and clicking “Highlight.”

Citations (0)
Some of your citations are legacy items.

Any citation created before July 30, 2012 will labeled as a “Cited page.” New citations will be saved as cited passages, pages or articles.

We also added the ability to view new citations from your projects or the book or article where you created them.

Notes (0)
Bookmarks (0)

You have no saved items from this article

Project items include:
  • Saved book/article
  • Highlights
  • Quotes/citations
  • Notes
  • Bookmarks
Cite this article

Cited article

Citations are available only to our active members.
Buy instant access to cite pages or passages in MLA, APA and Chicago citation styles.

(Einhorn, 1992, p. 25)

(Einhorn 25)

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25,

Note: primary sources have slightly different requirements for citation. Please see these guidelines for more information.

Cited article

Pharmaceutical Economics


Text size Smaller Larger Reset View mode
Search within

Search within this article

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

Full screen

matching results for page

    Questia reader help

    How to highlight and cite specific passages

    1. Click or tap the first word you want to select.
    2. Click or tap the last word you want to select, and you’ll see everything in between get selected.
    3. You’ll then get a menu of options like creating a highlight or a citation from that passage of text.

    OK, got it!

    Cited passage

    Citations are available only to our active members.
    Buy instant access to cite pages or passages in MLA, APA and Chicago citation styles.

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn, 1992, p. 25).

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn 25)

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences."1

    1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25,

    New feature

    It is estimated that 1 in 10 people have dyslexia, and in an effort to make Questia easier to use for those people, we have added a new choice of font to the Reader. That font is called OpenDyslexic, and has been designed to help with some of the symptoms of dyslexia. For more information on this font, please visit

    To use OpenDyslexic, choose it from the Typeface list in Font settings.

    OK, got it!

    Cited passage

    Thanks for trying Questia!

    Please continue trying out our research tools, but please note, full functionality is available only to our active members.

    Your work will be lost once you leave this Web page.

    Buy instant access to save your work.

    Already a member? Log in now.

    Author Advanced search


    An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.